Patents by Inventor Atsunori KANESHIGE

Atsunori KANESHIGE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STAT5 and STAT6 Inhibitors and Uses Thereof
    Publication number: 20230295200
    Abstract: Described herein are compounds of Formula I and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses as STAT5 and/or STAT6 inhibitors.
    Type: Application
    Filed: March 16, 2023
    Publication date: September 21, 2023
    Inventors: Shaomeng Wang, Atsunori Kaneshige, Longchuan Bai, Mi Wang, Jeanne Stuckey, Mingliang Wang, Renqi Xu
  • STAT5 and STAT6 Degraders and Uses Thereof
    Publication number: 20230295197
    Abstract: Described herein are compounds of Formula I and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses as STAT5 and/or STAT6 degraders.
    Type: Application
    Filed: March 16, 2023
    Publication date: September 21, 2023
    Inventors: Shaomeng Wang, Atsunori Kaneshige, Longchuan Bai, Mi Wang, Jeanne Stuckey, Donna McEachern, Mingliang Wang, Renqi Xu
  • PEPTIDOMIMETIC INHIBITORS OF THE WDR5-MLL INTERACTION
    Publication number: 20210130401
    Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3a, R3b, R4a, R4b, R5a and R5b are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition, disease, or disorder responsive to inhibition of the WDR5 interaction with its binding partners including, but not limited to, the WDR5-MLL protein-protein interaction.
    Type: Application
    Filed: May 15, 2018
    Publication date: May 6, 2021
    Inventors: Shaomeng Wang, Yangbing Li, Hacer Karatas, Liu Liu, Jeanne Stuckey, Yali Dou, Liyue Huang, Atsunori Kaneshige
  • Heterobicyclic compounds and their use for the treatment of tuberculosis
    Patent number: 10464926
    Abstract: It is an object of the present invention to provide a compound having an excellent antibacterial activity against tuberculosis bacteria, multidrug-resistant tuberculosis bacteria and/or non-tuberculous mycobacteria. Disclosed is a compound of the general formula (1): wherein each symbol is defined as described in the attached specification, or a salt thereof.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: November 5, 2019
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroshi Shimizu, Yoshikazu Kawano, Shunpei Ishikawa, Yukitaka Uematsu, Toshio Shinohara, Motohiro Itotani, Yoshikazu Haraguchi, Isao Takemura, Atsunori Kaneshige, Yuya Nakai, Norimitsu Hariguchi, Yohei Hayashi, Makoto Matsumoto
  • HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS
    Publication number: 20180312488
    Abstract: It is an object of the present invention to provide a compound having an excellent antibacterial activity against tuberculosis bacteria, multidrug-resistant tuberculosis bacteria and/or non-tuberculous mycobacteria. Disclosed is a compound of the general formula (1): wherein each symbol is defined as described in the attached specification, or a salt thereof.
    Type: Application
    Filed: July 9, 2018
    Publication date: November 1, 2018
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroshi SHIMIZU, Yoshikazu KAWANO, Shunpei ISHIKAWA, Yukitaka UEMATSU, Toshio SHINOHARA, Motohiro ITOTANI, Yoshikazu HARAGUCHI, Isao TAKEMURA, Atsunori KANESHIGE, Yuya NAKAI, Norimitsu HARIGUCHI, Yohei HAYASHI, Makoto MATSUMOTO
  • Heterobicyclic compounds and their use for the treatment of tuberculosis
    Patent number: 10053446
    Abstract: It is an object of the present invention to provide a compound having an excellent antibacterial activity against tuberculosis bacteria, multidrug-resistant tuberculosis bacteria and/or non-tuberculous mycobacteria. Disclosed is a compound of the general formula (1): wherein each symbol is defined as described in the attached specification, or a salt thereof.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: August 21, 2018
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroshi Shimizu, Yoshikazu Kawano, Shunpei Ishikawa, Yukitaka Uematsu, Toshio Shinohara, Motohiro Itotani, Yoshikazu Haraguchi, Isao Takemura, Atsunori Kaneshige, Yuya Nakai, Norimitsu Hariguchi, Yohei Hayashi, Makoto Matsumoto
  • HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS
    Publication number: 20170253576
    Abstract: It is an object of the present invention to provide a compound having an excellent antibacterial activity against tuberculosis bacteria, multidrug-resistant tuberculosis bacteria and/or non-tuberculous mycobacteria. Disclosed is a compound of the general formula (1): wherein each symbol is defined as described in the attached specification, or a salt thereof.
    Type: Application
    Filed: August 28, 2015
    Publication date: September 7, 2017
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroshi SHIMIZU, Yoshikazu KAWANO, Shunpei ISHIKAWA, Yukitaka UEMATSU, Toshio SHINOHARA, Motohiro ITOTANI, Yoshikazu HARAGUCHI, Isao TAKEMURA, Atsunori KANESHIGE, Yuya NAKAI, Norimitsu HARIGUCHI, Yohei HAYASHI, Makoto MATSUMOTO